<figure><img src="image_1.png" /></figure>

# The international exchange of *Drosophila melanogaster* strains

K.R. Cook* & A.L. Parks

Bloomington Drosophila Stock Center, Department of Biology, Indiana University, 1001 East 3rd Street, Bloomington, Indiana, 47405-7005, United States of America

*Corresponding author: kercook@indiana.edu

## Summary

*Drosophila melanogaster* has been a model organism for experimental research for more than a century, and the knowledge and associated genetic technologies accumulated around this species make it extremely important to contemporary biomedical research. A large international community of highly collaborative scientists investigate a remarkable diversity of biological problems using genetically characterised strains of Drosophila, and frequently exchange these strains across borders. Despite its importance to the study of fundamental biological processes and human disease-related cellular mechanisms, and the fact that it presents minimal health, agricultural or environmental risks, Drosophila can be difficult to import. The authors argue that streamlined regulations and practices would benefit biomedical research by lowering costs and increasing efficiencies.

## Keywords

*Drosophila melanogaster* - Importation - Insect - Model organism - Regulation.

## Introduction

For over a century, scientists have been investigating biological processes using the small fly, *Drosophila melanogaster* (or simply 'Drosophila' in common parlance). It is probably safe to say that more is known about the genes, genome and genetic regulation of cellular, developmental, physiological and behavioural processes in Drosophila than in any other multicellular organism. The genetic approaches and technologies available for Drosophila experimentation are extraordinarily advanced and have led to profound contributions to human health. This role of Drosophila as a 'research system' makes it different from most other insects described in this issue: it is not a disease vector, a significant agricultural pest or a biocontrol agent – and it is hard to envision Drosophila as a significant addition to the diet of anyone. It attracts the attention of scientists solely as a vehicle for discovery.

As directors of a major repository of Drosophila strains, the authors will try to give a glimpse into the significance of Drosophila research, an idea of the scale of the international exchange of Drosophila strains, and suggestions for promoting international collaborations by improving import regulations and practices.

## The importance of *Drosophila* to biological research

In the wild, *D. melanogaster* is attracted to a wide variety of foods and is among the first animals to find damaged fruit and lay eggs on it. Early development is extremely fast (roughly five days) and the young leave the fruit quickly to metamorphose into adults – as one might expect for an insect that relies on fleeting resources. This combination of adaptability and fast development predisposed Drosophila to life as a human commensal – a 'garbage species', like the rat, that has been associated for millennia with humans who have unwittingly provided it food and habitat. Drosophila has spread with human migrations and trade from its origin in southern Africa and is now found everywhere that people live [1, 2].

In the early 1900s, Thomas Hunt Morgan of Columbia University was the first scientist to take advantage of the flexibility and fast growth of Drosophila for extensive genetic experimentation. He needed an easily bred animal to show that inheritance in animals could not possibly be as straightforward as the principles outlined by Gregor Mendel from his work with peas – work that had only recently drawn the attention of scientists after languishing in an obscure journal for decades. To Morgan's surprise, the experiments in his
laboratory both validated and extended Mendel's conclusions [3, 4]. They led to the explosion of interest in genetics that remains unabated to this day.

Since then, Drosophila experiments have been associated with nearly every conceptual advance in genetics. In the first half of the 1900s, Drosophila studies were central in establishing broad areas of research, including mutagenesis, polygenic inheritance, and the behaviour of genes in populations. The latter half of the 20th century saw genetic analysis combined with increasingly sophisticated methods in microscopy, physiology and biochemistry to study ever-more-detailed Drosophila traits. Understanding the genetic control of development became a major interest, and with it came intensive efforts to define and dissect signalling pathways controlling cell growth, proliferation and differentiation. In fact, the major intracellular signalling pathways involved in human development, homeostasis and disease were discovered or fleshed out in Drosophila.

The advent of molecular biology technologies had a strong impact on Drosophila research. The development of cloning vectors in the 1980s for injection into fly eggs allowed DNA sequences to be stably inserted into chromosomes to create transgenes. Indeed, Drosophila was the first multicellular organism where it was possible to integrate DNA sequences that had been manipulated in the laboratory into the genome [5].

Experimental approaches now combine transgenes with the well-established modes of genetic analysis. They provide ways to determine the roles of proteins and RNAs in specific cells at specific times during development, where those proteins and RNAs reside inside cells, how gene expression changes are triggered by different environmental conditions, and much more. Together, they make the experimental genetics of Drosophila the most sophisticated among all multicellular organisms. Experiments can be undertaken efficiently and inexpensively that are impossible or extremely expensive in nearly every other animal or plant – especially in the realm of examining gene functions in individual cells or cell types in their normal tissue contexts. These advantages make Drosophila indispensable to contemporary biomedical research.

## Importance to human medicine

Those who work with insects wax poetic about them, but most people do not share their enthusiasm. It is often hard to convince non-scientists that there is any reason to study Drosophila other than to find ways to eradicate it. Nevertheless, most tissues and physiological processes in people have counterparts in flies and nearly every activity in human cells occurs in fly cells as well. Over all, Drosophila genes are remarkably similar to human genes. It is estimated that an astounding 85% of genes associated with human

diseases in the extensive Online Mendelian Inheritance in Man database have an equivalent gene in flies [6]. This means that characterising gene functions in flies usually has direct benefits in understanding biological processes in people.

In this century, research with Drosophila has focused heavily on exploring cellular aspects of human diseases. Significant discoveries related to cancer, neurodegenerative disorders, diabetes and other diseases have been made using the remarkable genetic tools available to Drosophila researchers (Table I). This work has not focused solely on the fly versions of human genes. Transgenic technologies have enabled geneticists to substitute human genes for fly genes in the flies themselves, and these ‘humanised’ flies are proving particularly important for dissecting the functions of protein domains and examining the effects of protein-drug interactions.

### Table I

<table><caption>A sampling of the many human diseases where Drosophila research has provided valuable insights</caption><thead><tr><td>Disease</td><td>Reference</td></tr></thead><tbody><tr><td>Addiction</td><td>[7]</td></tr><tr><td>Age-related disorders</td><td>[8]</td></tr><tr><td>Alcoholism</td><td>[9]</td></tr><tr><td>Alzheimer's disease</td><td>[10, 11]</td></tr><tr><td>Amyotrophic lateral sclerosis</td><td>[12, 13]</td></tr><tr><td>Angelman syndrome</td><td>[14]</td></tr><tr><td>Autism spectrum disorder</td><td>[15]</td></tr><tr><td>Cancer</td><td>[16]</td></tr><tr><td>Cardiomyopathies and other heart diseases</td><td>[17, 18]</td></tr><tr><td>Cystic fibrosis</td><td>[19]</td></tr><tr><td>Diabetes</td><td>[20]</td></tr><tr><td>Epilepsy and other seizure disorders</td><td>[21, 22]</td></tr><tr><td>Fragile X syndrome</td><td>[23]</td></tr><tr><td>Galactosaemia</td><td>[24]</td></tr><tr><td>Huntington's disease</td><td>[25]</td></tr><tr><td>Inflammatory bowel disease</td><td>[26]</td></tr><tr><td>Intellectual disability</td><td>[27]</td></tr><tr><td>Kidney diseases</td><td>[28]</td></tr><tr><td>Lysosomal storage diseases</td><td>[29]</td></tr><tr><td>Metabolic disorders and syndromes</td><td>[30]</td></tr><tr><td>Microcephaly</td><td>[31]</td></tr><tr><td>Mitochondrial-related disorders</td><td>[32]</td></tr><tr><td>Muscular dystrophies</td><td>[33]</td></tr><tr><td>Myotonic dystrophy</td><td>[34]</td></tr><tr><td>Neurofibromatosis</td><td>[35]</td></tr><tr><td>Obesity</td><td>[30]</td></tr><tr><td>Parkinson's disease</td><td>[36]</td></tr><tr><td>Creutzfeld-Jakob disease</td><td>[37]</td></tr><tr><td>Retinitis pigmentosa</td><td>[38]</td></tr><tr><td>Sleep disorders</td><td>[39]</td></tr><tr><td>Spinal muscular atrophy</td><td>[40]</td></tr><tr><td>Spinocerebellar ataxia</td><td>[41, 42]</td></tr></tbody></table>
An extraordinary example of the relevance of flies comes from the Undiagnosed Diseases Network. Many diseases in humans result from mutations, but it is often difficult to determine which particular gene has been disrupted to produce symptoms – even when genome sequence information is available. The Drosophila genes corresponding to candidate human genes can be disrupted in an effort to recapitulate cellular or physiological defects, and normal versions of the human genes can be introduced to ameliorate the defects. Experiments in flies by the Undiagnosed Diseases Network have now confirmed more than 25 gene-disease relationships [43].

Scientists often speak of 'model organisms' – species that are particularly well suited to dissecting biological phenomena. Often a model organism proves valuable to understanding one process but offers no advantages in investigating others. Few model organisms have had staying power as versatile research subjects, with large communities of researchers formed around their use. Drosophila is among the most popular because it continues to prove its research value.

## Drosophila stock resources and international exchange

More than 188,000 scientific papers have been published with 'Drosophila' in the title – 26,000 in the last decade alone [44]. A huge proportion of these studies have involved experiments with fly strains with defined genetic elements such as mutations or transgenes. Morgan and colleagues established an ethos of sharing their fly stocks with other scientists. Drosophila stocks built for studying one process often prove valuable in studying seemingly unrelated processes, and the fly research community takes pride in perpetuating the strong tradition of openly exchanging stocks.

The unrestricted exchange of stocks has been formalised through the establishment of public repositories that distribute useful stocks. The center managed by the authors – the Bloomington Drosophila Stock Center (BDSC) at Indiana University – is the largest. It supports the entire spectrum of research undertaken in over 3,500 Drosophila laboratories in 72 countries and currently maintains over 79,000 genetically defined stocks. Stock centres in Kyoto (Japan), Vienna (Austria) and Zürich (Switzerland) also serve the worldwide fly community and smaller centres serve specific research areas or geographical regions.

From 2011 to 2019, the BDSC exported a yearly average of 110,555 samples in 5,176 shipments to 809 laboratories in 460 institutions in 48 countries (Table II). Shipments in 2020 were unusually low due to the COVID-19 pandemic. From the shipping statistics of other stock centres, and a conservative estimate of shipments among individual researchers, the authors conclude that at least 10,000 boxes cross international borders every year from all sources. It is likely that more shipments of *D. melanogaster* are made worldwide than of any other live insect.

The BDSC uses both postal and courier services. In 2003–2005, it worked with the United States Postal Service and State Department, as well as international colleagues, to push for adoption of an amendment to the Universal Postal Convention, formally legalising the use of international mail to move Drosophila samples between countries [45].

## The international exchange of Drosophila stocks should be encouraged by all countries

Progress in exploring biological processes, determining the causes of genetic diseases, and devising treatments is

<caption>Table II</caption>

Summary statistics for recent Bloomington Drosophila Stock Center shipments

<table><thead><tr><td>Year</td><td>Total samples shipped</td><td>Total shipments</td><td>Total labs shipped to</td><td>Total institutions shipped to</td><td>Samples exported</td><td>Shipments exported</td><td>Laboratories exported to</td><td>Institutions exported to</td><td>Countries exported to</td></tr></thead><tbody><tr><td>2011</td><td>214,718</td><td>14,540</td><td>1,736</td><td>829</td><td>104,533</td><td>5,830</td><td>755</td><td>428</td><td>44</td></tr><tr><td>2012</td><td>222,981</td><td>12,822</td><td>1,788</td><td>871</td><td>116,973</td><td>5,149</td><td>782</td><td>455</td><td>44</td></tr><tr><td>2013</td><td>228,432</td><td>13,726</td><td>1,875</td><td>909</td><td>112,508</td><td>5,581</td><td>825</td><td>475</td><td>47</td></tr><tr><td>2014</td><td>236,340</td><td>13,739</td><td>1,864</td><td>903</td><td>116,724</td><td>5,496</td><td>796</td><td>456</td><td>45</td></tr><tr><td>2015</td><td>243,148</td><td>14,180</td><td>1,947</td><td>930</td><td>114,983</td><td>5,465</td><td>833</td><td>462</td><td>46</td></tr><tr><td>2016</td><td>217,072</td><td>13,521</td><td>1,988</td><td>956</td><td>106,326</td><td>5,175</td><td>854</td><td>480</td><td>53</td></tr><tr><td>2017</td><td>218,429</td><td>13,672</td><td>1,978</td><td>977</td><td>111,007</td><td>5,124</td><td>828</td><td>474</td><td>50</td></tr><tr><td>2018</td><td>222,975</td><td>13,173</td><td>1,976</td><td>972</td><td>110,560</td><td>4,488</td><td>820</td><td>467</td><td>52</td></tr><tr><td>2019</td><td>204,672</td><td>12,736</td><td>1,950</td><td>973</td><td>101,383</td><td>4,277</td><td>790</td><td>447</td><td>51</td></tr><tr><td>2020</td><td>160,105</td><td>9,044</td><td>1,736</td><td>767</td><td>83,587</td><td>2,996</td><td>719</td><td>422</td><td>41</td></tr></tbody></table>
obviously beneficial, and Drosophila is vital to these efforts. Scientists need to exchange stocks with collaborators across borders and obtain stocks from repositories. Consequently, lowering barriers to importing Drosophila should be a priority for regulatory officials in every country.

Beyond being 'the right thing to do', easing Drosophila importation usually aligns with national research priorities. For example, funding agencies in the United States of America (USA) have invested heavily in Drosophila research and resources. The RePORTER database [46] shows that the National Institutes of Health funded more than US$ 520 million in Drosophila research grants last year (2021). The National Science Foundation also invests strongly in fly research while other agencies, such as the United States Department of Agriculture (USDA), also fund projects. National agencies in many other countries provide substantial support. Non-governmental organisations – such as the Howard Hughes Medical Institute, the Muscular Dystrophy Association and the Wellcome Trust – also generously support Drosophila research.

Most countries do not support domestic Drosophila repositories, so their scientists rely heavily on external stock centres. In turn, the stock centres depend on scientists outside their own countries to donate important stocks and to cover costs through purchases (nearly 40% of routine BDSC operating expenses are paid from non-US revenue). This mutually beneficial relationship depends on efficient import practices. When a country establishes procedures that discourage scientists from importing model organisms, it not only undermines the well-being of stock centres, it places its own domestic research programmes at a disadvantage.

## Drosophila melanogaster strains are safe

Drosophila melanogaster poses essentially no risks. It is not a major agricultural pest because, unlike the Mediterranean fruit fly or 'medfly' (Ceratitis capitata), it cannot harm growing fruit. (The fact that Drosophilids are often called 'fruit flies' makes some people assume that they are similar to medflies and other Tephritids, but they are very different and even untrained people can distinguish them readily.) Its only interaction with the agricultural supply chain is relatively minor: it can be a nuisance for fruit processors – hence its other common names, pomace (mashed fruit) fly and vinegar fly. Likewise, it poses no problems as an invasive species; it had already spread to most of the world before geneticists got interested in it. Endangered species regulations are irrelevant.

Drosophila poses no health risks. It does not bite or sting. It is not the intermediate host for any parasite, nor is it naturally infected by any pathogen of human or agricultural concern. Likewise, it is nearly impossible for laboratory cultures to be

contaminated with a microbe of concern. Nearly all experiments are conducted with stocks whose origins can be traced to flies brought into laboratories in the early-to-mid-20th century. Most fly geneticists will spend their entire careers never having worked with wild-caught flies. The cultures are maintained on artificial media with nothing living from the outdoors introduced intentionally. Additionally, most experiments involve strains that must be used in closed facilities approved for transgenic animals, where exposure of flies to pathogenic microbes is also minimal. When flies are shipped between laboratories, the goal is to transfer them from one closed facility to another with no release into nature.

Can transgenes make Drosophila strains dangerous? The authors are confident that none of the nearly 47,000 transgenes in BDSC stocks and no transgenes in any other repositories increase risks, and that almost all of the more than 145,000 transgenes currently listed in FlyBase [47] from the fly literature are harmless. To their knowledge, the only unintentional environmental release of transgenic flies that would pose higher-than-usual risks to the genetic structures of natural populations would be from 'gene drive' experiments that artificially accelerate the spread of transgenes through laboratory-created populations – usually to model the transgenic control of disease vectors such as mosquitoes [48]. The few researchers investigating gene drive in flies use strict containment measures. The authors are aware of only one line of investigation in which fly transgenes have presented disease risks to other organisms: examining the cellular effects of expressing transgene-encoded prion proteins [37]. That research has also been limited to a small number of laboratories and carried out under strict conditions.

In both of these rare situations, the relevant experimental conditions have been created by combining transgenes in progeny via the mating of parental strains. The parental strains, by themselves, pose no increased risks and could, in principle, be moved between labs without undue concern, even though their distribution has been tightly controlled.

These facts lead to the conclusion that *D. melanogaster* is an innocuous organism, reared under clean conditions, which carries transgenes that do not increase risks in the strains that would be moved. It should, consequently, be one of the easiest research animals to exchange between countries and, in the opinion of the authors, every country should encourage its importation to further scientific progress.

Box 1 discusses other *Drosophila* species.

## Exchanging Drosophila strains between countries is more difficult than it should be

To ship Drosophila, the BDSC puts adults into plastic vials with solidified food, where they lay eggs. As long as the vials
## Box 1

### Other *Drosophila* species

In popular culture and most scientific discussions, the word 'Drosophila' usually refers to *Drosophila melanogaster* – even though there are hundreds of species in the genus *Drosophila*. The authors use 'Drosophila' in this vernacular sense and do not italicise it when used as a common name for *D. melanogaster* – as is becoming a more frequent practice in the scientific literature. Nevertheless, many other species in the genus *Drosophila* are routinely reared in laboratories. Indeed, there are non-melanogaster strains that have been maintained for nearly as long as the oldest *D. melanogaster* strains. Some species are well suited for studying specific biological phenomena, but many experimental uses of non-melanogaster species arise from their being evolutionarily related to *D. melanogaster*. Large strain collections are maintained by government-sponsored repositories at Cornell University (United States of America), the Kyoto Institute of Technology and Kyorin University (both in Japan). Non-melanogaster strains are exchanged internationally, although not as frequently as melanogaster strains. *Drosophila suzukii* is the only species in the genus that poses a significant agricultural risk and is studied primarily in the context of pest control. Its movement should be carefully controlled, but other *Drosophila* species are like *D.melanogaster* in presenting minimal risk. Because of their importance to research, the authors feel these species should also receive special consideration when being imported for use at closed facilities.

do not get too cold or hot, or take too long en route, stocks can be propagated from these starter cultures. Of the approximately 5,000 shipments the BDSC exports every year, roughly 15% arrive with dead cultures. The BDSC provides free replacements if customers pay shipping costs. Losses from weather and transportation conditions are inevitable and the BDSC largely accepts them as 'part of doing business', but most losses come from delivery delays associated with import regulations and practices. The BDSC takes regulatory compliance seriously, but satisfying import officials in every country often seems like an unattainable goal. Here, the authors will make a few points about importation that will, admittedly, reflect their frustration.

### Import practices should reflect the identity of the animal and how it was raised

One major improvement would be for practices to make sense for the animals being imported. Import rules seem to be predicated on all animals being treated the same and therefore requiring similar paperwork and inspections. Consequently, the BDSC often completes paperwork for Drosophila that makes no sense. Some countries insist on receiving export health certificates signed by a government-approved veterinarian – an illogical and expensive 'one-size-fits-all' requirement that makes sense for pets

and farm animals, but little or no sense for model organisms raised in isolation. It is particularly difficult to justify for Drosophila because veterinarians generally have little knowledge of insects or insect diseases, and there are no formal guidelines for 'giving a fly a check-up'. Veterinarians rely on what they know about Drosophila in general and on the fact that the flies are reared in a laboratory to certify the absence of diseases of public health concern – two things that obviously do not require culture-by-culture inspection.

Nearly all biomedical research with animals is conducted with fewer than two dozen species, which are reared and used in closed facilities. Given the simplicity of this situation, the authors contend that model organisms should be given special consideration and expedited processing. The European Union (EU) has recently taken steps in this direction by exempting research organisms from domestic veterinary inspections upon arrival [49]. Likewise, USDA regulations were recently changed to exempt many *D. melanogaster* strains from import permit requirements and to allow the substitution of simplified import documents [50, 51].

Nevertheless, agency decisions in some countries have made model organism importation unreasonably difficult. For example, most model organisms cannot be imported into the United Kingdom via courier services because inspectors at major courier hubs are authorised to clear shipments of only large farm animals. The World Organisation for Animal Health and other organisations with influence over import regulations and practices should strongly support the streamlined importation of research organisms.

### Permits should be long lasting

In many countries, a specific import permit is required for each shipment. This is a burden when many projects require multiple shipments and when the regulatory considerations are the same for all strains, regardless of genotype. Permits for multiple shipments would save everyone time and effort.

### Fees should be appropriate

Application and inspection fees can be expensive. Until the EU changed its regulations, scientists were often paying hundreds of euros in veterinary fees per box of flies (for which repositories could be charging as little as € 3). Fees should cover actual costs for justifiable expenses.

### Import rules should be articulated clearly

The BDSC has seen from its interactions with import officials that there can be considerable uncertainty about applying regulations to Drosophila. Import officials often find it difficult to advise scientists on importing flies instead of mammals, and shipments are treated inconsistently in many, if
not most, countries. The authors hope that the articles in this
issue will spur regulatory agencies to clarify internal prac-
tices regarding insect importation.

In general, repositories do not have the personnel resources
to keep up with the import practices of all the countries they
serve and to supply scientists with up-to-date information.
Users are often surprised when they learn repositories can-
not provide all the paperwork necessary for importation
and that they must acquire permits themselves. Ideally,
scientists would ascertain what kinds of pre-approval and
documentation they need for their countries and pass that
information along to repositories and their colleagues, but
requirements are usually complicated and often require
lengthy registration and application processes, and it is
rare to find a scientist who has mastered the intricacies
well enough to provide definitive explanations. There is an
immense need for instructions on exactly how to import
insects into most countries. This lack of explicit guidance
has led to an enormous amount of misinformation among
scientists, and it is often hard to convince them that their
workarounds and impromptu solutions do not comply with
the regulations of their own countries.

The BDSC is very willing to work with scientists and import
officials to assemble instructions for importing Drosophila
into other countries and to post them on its website in the
same way it has provided guidance on US importation [50].
It is, nevertheless, difficult to interest busy scientists in the
task and nearly impossible for the BDSC to interact with
government officials in other countries without a domestic
intermediary. It would be much better for regulatory agen-
cies themselves to provide clear guidance specifically for
importing insects.

Conclusions

Import officials probably wonder why scientists do not do a
better job complying with regulations and are undoubtedly
unhappy that they need to use their discretion so often to
release shipments for delivery when documents are missing
or incorrect. Scientists need to learn the rules and under-
stand the practices of their own countries better and engage
with import officials for advice. Nevertheless, the complexity
of requirements and the unavailability of specific guidance
make importation genuinely confusing and difficult. The
authors know improvements are possible because com-
pliance within the USA has improved since the BDSC and
Department of Agriculture began working together to pro-
vide clearer import instructions for Drosophila, and as the
USDA has simplified regulations and processes.

The authors hope this issue of articles on the international shipment of insects will help to bridge the knowledge and cultural divides between scientists and regulators. The world benefits tremendously from the work of the Drosophila research community, and regulations and practices that make collaborations among fly laboratories easier help everyone.

Acknowledgements

The authors would like to thank Kim Cook, Cale Whitworth, Sam Zheng and Thom Kaufman for their helpful input. They are also indebted to FlyBase for Drosophila literature information provided under funding from National Institutes of Health Grant U41 HG000739 and the British Medical Research Council. The Bloomington Drosophila Stock Center is supported by National Institutes of Health Grant P40 OD018537.

Les échanges de souches de *Drosophila melanogaster*
à l'échelle internationale

K.R. Cook & A.L. Parks

Résumé

Drosophila melanogaster sert d'organisme modèle pour la recherche expérimentale depuis plus d'un siècle, aboutissant à une somme de connaissances sur cette espèce et sur les technologies génétiques qui lui sont associées qui la rendent extrêmement importante pour la recherche biomédicale contemporaine. Aujourd'hui, une vaste communauté internationale de chercheurs dotés d'une culture élevée de la collaboration étudie un nombre impressionnant de problèmes biologiques en utilisant des souches de drosophile caractérisées sur le plan génétique, ce qui conduit à un partage fréquent de ces souches au-delà des frontières nationales. Or, il est parfois difficile d'importer des drosophiles, en dépit de l'importance de cette espèce pour l'étude des processus biologiques fondamentaux et des mécanismes cellulaires liés aux maladies humaines, et du risque minime qu'elle représente pour la santé, l'agriculture ou l'environnement. Les auteurs estiment qu'une rationalisation des réglementations et des pratiques serait bénéfique
# El intercambio internacional de cepas de Drosophila melanogaster

K.R. Cook & A.L. Parks

## Resumen

Drosophila melanogaster es un organismo modelo para las investigaciones experimentales desde hace más de un siglo. El acervo de conocimientos y las correspondientes tecnologías genéticas que se han ido acumulando en relación con esta especie hacen de ella un elemento de suma importancia para la actual investigación biomédica. Hay una gran comunidad internacional de científicos que, trabajando en estrecha colaboración, investigan muy diversos problemas biológicos sirviéndose de cepas de Drosophila genéticamente caracterizadas, para lo cual intercambian a menudo estas cepas de uno a otro país. Pese a su importancia para el estudio de procesos biológicos fundamentales y de mecanismos celulares ligados a enfermedades humanas, y pese a que los riesgos sanitarios, agrícolas o ambientales que entraña son mínimos, la importación de Drosophila puede resultar dificultosa. Los autores postulan que la simplificación de procesos y reglamentos sería beneficiosa para la investigación biomédica, pues reduciría costos y permitiría ganar en eficiencia.

## Palabras clave

Drosophila melanogaster - Importación - Insecto - Organismo modelo - Regulación.

## References

[1] Arguello J.R., Laurent S. & Clark A.G. (2019). – Demographic history of the human commensal *Drosophila melanogaster*. *Genome Biol. Evol.*, **11** (3), 844–854. https://doi.org/10.1093/gbe/evz022

[2] Mansourian S., Enjin A., Jirle E.V., Ramesh V., Rehermann G., Becher P.G., Pool J.E. & Stensmyr M.C. (2018). – Wild African *Drosophila melanogaster* are seasonal specialists on marula fruit. *Curr. Biol.*, **28** (24), 3960–3968. https://doi.org/10.1016/j.cub.2018.10.033

[3] Sturtevant A.H. (1959). – Thomas Hunt Morgan, 1866–1945. *Biogr. Mem. Natl Acad. Sci.*, **33**, 283–325. Available at: http://www.nasonline.org/publications/biographical-memoirs/memoir-pdfs/morgan-thomas-hunt.pdf (accessed on 10 September 2021).

[4] Sturtevant A.H. (1965). – A history of genetics. Harper & Row, New York, United States of America, 165 pp.

[5] Spradling A.C. & Rubin G.M. (1982). – Transposition of cloned P-elements into *Drosophila* germ line chromosomes. *Science*, **218** (4570), 341–347. https://doi.org/10.1126/science.6289435

[6] Baldridge D., Wangler M.F., Bowman A.N., Yamamoto S., Network U.D., Schedl T., Pak S.C., Postlethwait J.H., Shin J., Solnica-Krezel L., Bellen H.J. & Westerfield M. (2021). – Model organisms contribute to diagnosis and discovery in the Undiagnosed

Diseases Network: current state and a future vision. *Orphanet J. Rare Dis.*, **16** (1), 206. https://doi.org/10.1186/s13023-021-01839-9

[7] Ryvkin J., Bentzur A., Zer-Krispil S. & Shohat-Ophir G. (2018). – Mechanisms underlying the risk to develop drug addiction, insights from studies in *Drosophila melanogaster*. *Front. Physiol.*, **9**, 327. https://doi.org/10.3389/fphys.2018.00327

[8] Piper M.D.W. & Partridge L. (2018). – *Drosophila* as a model for ageing. *Biochim. Biophys. Acta*, **1864** (9, Pt A), 2707–2717. https://doi.org/10.1016/j.bbadis.2017.09.016

[9] Lathen D.R., Merrill C.B. & Rothenfluh A. (2020). – Flying together: *Drosophila* as a tool to understand the genetics of human alcoholism. *Int. J. Mol. Sci.*, **21** (18), 6649. https://doi.org/10.3390/ijms21186649

[10] Tsuda L. & Lim Y.M. (2018). – Alzheimer's disease model system using *Drosophila*. *Adv. Exp. Med. Biol.*, **1076**, 25–40. https://doi.org/10.1007/978-981-13-0529-0_3

[11] Tue N.T., Dat T.Q., Ly L.L., Anh V.D. & Yoshida H. (2020). – Insights from *Drosophila melanogaster* model of Alzheimer's disease. *Front. Biosci.*, **25** (1), 134–146. https://doi.org/10.2741/4798

[12] Liguori F., Amadio S. & Volonté C. (2021). – Fly for ALS: *Drosophila* modeling on the route to amyotrophic lateral sclerosis modifiers. *Cell Mol. Life Sci.*, **78** (17–18), 6143–6160. https://doi.org/10.1007/s00018-021-03905-8
[13] Goodman L.D. & Bonini N.M. (2020). – New roles for canonical transcription factors in repeat expansion diseases. *Trends Genet.*, **36**(2), 81–92. https://doi.org/10.1016/j.tig.2019.11.003

[14] Jana N.R. (2012). – Understanding the pathogenesis of Angelman syndrome through animal models. *Neural Plast.*, **2012**, 710943. https://doi.org/10.1155/2012/710943

[15] Bellosta P. & Soldano A. (2019). – Dissecting the genetics of autism spectrum disorders: a *Drosophila* perspective. *Front. Physiol.*, **10**, 987. https://doi.org/10.3389/fphys.2019.00987

[16] Chatterjee D. & Deng W.M. (2019). – *Drosophila* model in cancer: an introduction. *Adv. Exp. Med. Biol.*, **1167**, 1–14. https://doi.org/10.1007/978-3-030-23629-8_1

[17] Zhu S., Han Z., Luo Y., Chen Y., Zeng Q., Wu X. & Yuan W. (2017). – Molecular mechanisms of heart failure: insights from *Drosophila*. *Heart Fail. Rev.*, **22** (1), 91–98. https://doi.org/10.1007/s10741-016-9590-3

[18] Ma L. (2016). – Can the *Drosophila* model help in paving the way for translational medicine in heart failure? *Biochem. Soc. Trans.*, **44** (5), 1549–1560. https://doi.org/10.1042/BST20160017C

[19] Kim K., Lane E.A., Saftien A., Wang H., Xu Y., Wirtz-Peitz F. & Perrimon N. (2020). – *Drosophila* as a model for studying cystic fibrosis pathophysiology of the gastrointestinal system. *Proc. Natl Acad. Sci. USA*, **117** (19), 10357–10367. https://doi.org/10.1073/pnas.1913127117

[20] Chatterjee N. & Perrimon N. (2021). – What fuels the fly: energy metabolism in *Drosophila* and its application to the study of obesity and diabetes. *Sci. Adv.*, **7** (24), eabg4336. https://doi.org/10.1126/sciadv.abg4336

[21] Takai A., Yamaguchi M., Yoshida H. & Chiyonobu T. (2020). – Investigating developmental and epileptic encephalopathy using *Drosophila melanogaster*. *Int. J. Molec. Sci.*, **21** (17), 6442. https://doi.org/10.3390/ijms21176442

[22] Lasko P. & Lüthy K. (2021). – Investigating rare and ultrarare epilepsy syndromes with *Drosophila* models. *Fac. Rev.*, **10**, 10. https://doi.org/10.12703/r/10-10

[23] Drozd M., Bardoni B. & Capovilla M. (2018). – Modeling Fragile X Syndrome in *Drosophila*. *Front. Molec. Neurosci.*, **11**, 124. https://doi.org/10.3389/fnmol.2018.00124

[24] Daenzer J.M. & Fridovich-Keil J.L. (2017). – *Drosophila melanogaster* models of galactosemia. *Curr. Topics Dev. Biol.*, **121**, 377–395. https://doi.org/10.1016/bs.ctdb.2016.07.009

[25] Rosas-Arellano A., Estrada-Mondragón A., Piña R., Mantellero C.A. & Castro M.A. (2018). – The tiny *Drosophila melanogaster* for the biggest answers in Huntington’s disease. *Int. J. Molec. Sci.*, **19** (8), 2398. https://doi.org/10.3390/ijms19082398

[26] Capo F., Wilson A. & Di Cara F. (2019). – The intestine of *Drosophila melanogaster*: an emerging versatile model system to study intestinal epithelial homeostasis and host-microbial interactions in humans. *Microorganisms*, **7** (9), 336. https://doi.org/10.3390/microorganisms7090336

[27] Coll-Tané M., Krebbers A., Castells-Nobau A., Zweier C. & Schenck A. (2019). – Intellectual disability and autism spectrum disorders ‘on the fly’: insights from *Drosophila*. *Dis. Model. Mech.*, **12** (5), dmm039180. https://doi.org/10.1242/dmm.039180

[28] Millet-Boureima C., He S., Le T.B.U. & Gamberi C. (2021). – Modeling neoplastic growth in renal cell carcinoma and polycystic

kidney disease. *Int. J. Molec. Sci.*, **22** (8), 3918. https://doi.org/10.3390/ijms22083918

[29] Rigon L., De Filippis C., Napoli B., Tomanin R. & Orso G. (2021). – Exploiting the potential of *Drosophila* models in lysosomal storage disorders: pathological mechanisms and drug discovery. *Biomedicines*, **9** (3), 268. https://doi.org/10.3390/biomedicines9030268

[30] Musselman L.P. & Kühnlein R.P. (2018). – *Drosophila* as a model to study obesity and metabolic disease. *J. Experim. Biol.*, **221** (Suppl. 1), jeb163881. https://doi.org/10.1242/jeb.163881

[31] Robinson B.V., Faundez V. & Lerit D.A. (2020). – Understanding microcephaly through the study of centrosome regulation in *Drosophila* neural stem cells. *Biochem. Soc. Trans.*, **48** (5), 2101–2115. https://doi.org/10.1042/BST20200261

[32] Chen Z., Zhang F. & Xu H. (2019). – Human mitochondrial DNA diseases and *Drosophila* models. *J. Genet. Genomics*, **46** (4), 201–212. https://doi.org/10.1016/j.jgg.2019.03.009

[33] Potikanond S., Nimlamool W., Noordermeer J. & Fradkin L.G. (2018). – Muscular dystrophy model. *Adv. Exp. Med. Biol.*, **1076**, 147–172. https://doi.org/10.1007/978-981-13-0529-0_9

[34] Chakraborty M., Llamusi B. & Artero R. (2018). – Modeling of myotonic dystrophy cardiac phenotypes in *Drosophila*. *Front. Neurol.*, **9**, 473. https://doi.org/10.3389/fneur.2018.00473

[35] King L.B., Koch M., Murphy K.R., Velazquez Y., Ja W.W. & Tomchik S.M. (2016). – Neurofibromin loss of function drives excessive grooming in *Drosophila*. *G3 (Bethesda)*, **6** (4), 1083–1093. https://doi.org/10.1534/g3.115.026484

[36] Aryal B. & Lee Y. (2019). – Disease model organism for Parkinson disease: *Drosophila melanogaster*. *BMB Rep.*, **52** (4), 250–258. https://doi.org/10.5483/BMBRep.2019.52.4.204

[37] Fernandez-Funez P., Sanchez-Garcia J. & Rincon-Limas D.E. (2017). – *Drosophila* models of prionopathies: insight into prion protein function, transmission, and neurotoxicity. *Curr. Opin. Genet.*, **44**, 141–148. https://doi.org/10.1016/j.gde.2017.03.013

[38] Gaspar P., Almudi I., Nunes M.D.S. & McGregor A.P. (2019). – Human eye conditions: insights from the fly eye. *Hum. Genet.*, **138** (8–9), 973–991. https://doi.org/10.1007/s00439-018-1948-2

[39] Chakravarti L., Moscato E.H. & Kayser M.S. (2017). – Unraveling the neurobiology of sleep and sleep disorders using *Drosophila*. *Curr. Topics Dev. Biol.*, **121**, 253–285. https://doi.org/10.1016/bs.ctdb.2016.07.010

[40] Aquilina B. & Cauchi R.J. (2018). – Modelling motor neuron disease in fruit flies: lessons from spinal muscular atrophy. *J. Neurosci. Meth.*, **310**, 3–11. https://doi.org/10.1016/j.jneumeth.2018.04.003

[41] Ueyama M. & Nagai Y. (2018). – Repeat expansion disease models. *Adv. Exp. Med. Biol.*, **1076**, 63–78. https://doi.org/10.1007/978-981-13-0529-0_5

[42] Krench M. & Littleton J.T. (2017). – Neurotoxicity pathways in *Drosophila* models of the polyglutamine disorders. *Curr. Topics Dev. Biol.*, **121**, 201–223. https://doi.org/10.1016/bs.ctdb.2016.07.006

[43] Link N. & Bellen H.J. (2020). – Using *Drosophila* to drive the diagnosis and understand the mechanisms of rare human diseases. *Development*, **147** (21), dev191411. https://doi.org/10.1242/dev.191411

[44] Google Scholar (2021). – Google Scholar database. Alphabet, Inc., Mountain View, United States of America. Available at: https://scholar.google.com/ (accessed on 10 September 2021).
[45] Universal Postal Union (2005). – Decisions of the 2004 Bucharest Congress: final text of the Acts signed in Bucharest: decisions other than those amending the Acts. International Bureau of the Universal Postal Union, Berne, Switzerland, 311 pp. Available at: https://www.upu.int/UPU/media/upu/files/UPU/aboutUpu/acts/actsOfPreviousCongress/act2004DecisionsBucarestEn.pdf (accessed on 10 September 2021).

[46] United States National Institutes of Health (NIH) (2021). – RePORTER database. NIH, Bethesda, United States of America. Available at: https://reporter.nih.gov/ (accessed on 15 May 2021).

[47] Larkin A., Marygold S.J. [...] & FlyBase Consortium (2021). – FlyBase: updates to the *Drosophila melanogaster* knowledge base. *Nucleic Acids Res.*, **49** (D1), D899–D907. https://doi.org/10.1093/nar/gkaa1026

[48] Akbari O.S., Bellen H.J. [...] & Wildonger J. (2015). – Safeguarding gene drive experiments in the laboratory. *Science*, **349** (6251), 927–929. https://doi.org/10.1126/science.aac7932

[49] European Union (EU) (2017). – Regulation (EU) 2017/625 of the European Parliament and of the Council of 15 March 2017 on official controls and other official activities performed to ensure the application of food and feed law, rules on animal health and welfare, plant health and plant protection products. Document 32017R0625. *Off. J. Eur. Union*, **L 95**, 142 pp. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0625 (accessed on 10 September 2021).

[50] Cook K.R. (2021). – United States import documents. Bloomington Drosophila Stock Center, Bloomington, United States of America. Available at: https://bdsc.indiana.edu/information/permits/index.html (accessed on 10 September 2021).

[51] United States Department of Agriculture (USDA) (2021). – Movement of organisms modified or produced through genetic engineering. US National Archives, Washington, DC, United States of America. Available at: https://www.ecfr.gov/current/title-7/subtitle-B/chapter-III/part-340 (accessed on 10 September 2021).

© 2022 Cook K.R. & Parks A.L.; licensee the World Organisation for Animal Health. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (https://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WOAH or this article endorse any specific organisation, product or service. The use of the WOAH logo is not permitted. This notice should be preserved along with the article's original URL.